Posts by Simon Erickson

Article

STAAR Surgical’s Q2 Results are Looking Sharp

Sep 18, 2024

The vision correction innovator continues to gain market share on LASIK.

Article

Why I Bought and then Sold Celsius This Summer

Sep 13, 2024

The temperature's rising as I've gone from bullish to bearish about Celsius this summer. The experience highlights several behavioral biases we constantly face as investors.

Article

United Therapeutics is Leading a Biotech Revolution. Here’s Why it…

Sep 4, 2024

First it treated an untreatable disease. Now it's disrupting the entire organ transplant industry. Here's why United Therapeutics needs to be a stock on your radar.

Article

Supermicro’s Selloff is an Opportunity. Here’s Why I’m Buying the…

Aug 29, 2024

Supermicro's stock is up 2,500% during the past 3 years and has now fallen 50% in August. What the heck is going on?

Premium Advisor Update

August 2024 Watch List of New Stock Ideas

Aug 23, 2024

Article

TransMedics’ New “Organs as a Service” Market is Winning the…

Aug 21, 2024

The "organ transplant as a service" market is taking the medical world by storm. How long can the accelerated growth rates continue?

Article

What’s NVIDIA’s Stock Really Worth? Now’s the Right Time to…

Jul 22, 2024

It's a race to develop the world's highest-performance AI accelerators. Will the Computing King continue to wear the AI crown?

Article

Domino’s Pizza: On Sale, But Still Not a Bargain

Jul 18, 2024

The pizza chain's stock went on sale today, though it still doesn't look particularly appetizing.

Article

NIKE: Short-Term Pain, Long-Term Gain?

Jul 16, 2024

Is the global athletic wear king current an excellent investment opportunity?

Premium Advisor Update

Simon’s July 2024 Conviction Rating Review

Jul 14, 2024

Article

ASML is About to Have a Monster Year; Upgrading Our…

Jul 2, 2024

The Dutch lithography equipment supplier looks like it'll be very busy in the second half of 2024.

Article

Cassava Sciences: Is The Fraud Investigation Just Smoke…or an Actual…

Jul 1, 2024

This micro-cap biotech company is working on an innovative cure to Alzheimer's Disease but is surrounded by controversy. Is it worth the risk for investors?

Premium Advisor Update

Simon’s June 2024 Conviction Rating Review

Jun 15, 2024

Article

Illumina Officially Ends Its Quest for the Holy GRAIL

Jun 7, 2024

After feeling the heat from investors, customers, and regulators, Illumina has finally agreed to divest GRAIL.

Article

Tesla “the AI Company” is Worth $645 Per Share. Here’s…

May 21, 2024

If Tesla executes on its FSD ambitions, the rewards for investors could be massive.

Premium Advisor Update

Simon’s May 2024 Conviction Rating Review

May 15, 2024

Article

Tesla “the Car Company” is Worth $104 Per Share. Here’s…

May 14, 2024

Tesla's stock has a lot riding on its FSD future. Will Elon successfully navigate the opportunity?

Article

Tesla’s Growth Will Accelerate Into 2030

May 9, 2024

Despite some near-term speedbumps, strong global demand for EVs should accelerate Tesla's vehicle sales through 2030.

Article

5 Key Takeaways Investors Should Know About Tesla

May 7, 2024

The EV innovator is facing some near-term headwinds, but is still full-speed ahead when it comes to global expansion.

Article

What’s Tesla Really Worth? Now’s the Right Time to Find…

May 6, 2024

How much is Tesla's stock really worth? 7investing CEO Simon Erickson will be answering one of investing's biggest questions this week.

Article

The Trade Desk is Worth $62 Per Share. Here’s Why.

Apr 25, 2024

Is the stock of this digital advertising innovator significantly overpriced? We dug deep and let the numbers do the talking.

Premium Advisor Update

Simon’s April 2024 Conviction Rating Review

Apr 15, 2024

Article

Coupang is Worth $19.25 Per Share, But With Hidden Upside.…

Apr 12, 2024

The base case of my Discounted Cash Flow predicts Coupang's stock is currently worth $19.25 per share. But like we saw this morning, it also has some excellent hidden optionality.

Podcast

ShockWave Medical Receives a Buyout Offer

Apr 8, 2024

Shockwave Medical (Nasdaq: SWAV), the innovative leader in intravascular lithotripsy, has received a $335 per share all-cash acquisition offer from Johnson & Johnson (NYSE: JNJ). 

Article

Contest Matchup #6: CRISPR Therapeutics vs Seres Therapeutics

Apr 2, 2024

Two biotech companies go head-to-head in our sixth Stockpicking matchup.

Article

Contest Matchup #5: Intel vs Super Micro Computer

Mar 28, 2024

Two semiconductor companies go head-to-head in the fifth of our Stockpicking matchups.